Recruiting
Phase 2
Phase 3

Mangaciclanol

Sponsor:

GE Healthcare

Code:

NCT07472491

Conditions

Known or Highly Suspected Central Nervous System (CNS) Lesion

Known or Highly Suspected Body (Excluding CNS) Lesion

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL

MRI Scan

Gadobutrol

Study Details

Brief summary:

This is an operationally combined Phase 2/3 study, which will be conducted and evaluated in 2 distinct parts:

  • Phase 2: Prospective, adaptive, multicenter, non-randomized, single-blind, dose-finding, including participants with known or highly suspected lesions of the CNS. The aim of the Phase 2 part is to identify an optimized dose of mangaciclanol for the Phase 3 part of the study.
  • Phase 3: Prospective, multicenter, randomized, controlled, single-blind, cross-over, including participants with known or highly suspected lesions of the CNS or body. The aim of the Phase 3 part is to further evaluate the efficacy and safety of mangaciclanol-enhanced MRI for the detection and characterization of lesions of the CNS or body.

The investigational medicinal products (IMPs) used during the trial are mangaciclanol and gadobutrol (comparator IMP).

Primary and key secondary efficacy analyses will be based on independent central blinded image evaluation (BIE), and Phase 2 data will be analyzed prior to commencement of Phase 3.

Conditions

Known or Highly Suspected Central Nervous System (CNS) Lesion

Known or Highly Suspected Body (Excluding CNS) Lesion

Study ID

NCT07472491

Start date

Apr 1, 2026

Status verified date

Apr, 2026

Completion date

Nov 30, 2027

Anticipated

Primary completion date

Nov 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • The participant is of legal majority age, as defined by local laws and regulations at the time of signing the ICF.
  • The participant is able and willing to comply with study procedures as described in the protocol.
  • The participant has read, understood, signed and dated the ICF prior to any study procedures.
  • Phases 2 and 3 CNS: Participants presenting with known or highly suspected enhancing CNS lesions referred as part of standard care for contrast-enhancing MRI of the CNS. The suspicion may be based on a previous imaging procedure such as computed tomography (CT), positron emission tomography (PET)/CT or MRI performed within 12 months prior to ICF signature.
  • Phase 3 body only: Participants presenting with known or highly suspected enhancing lesions in at least 1 body region (i.e., head and neck, thorax, abdomen, pelvis, and musculoskeletal system \[only breast in the United States in compliance with local approved indications of gadobutrol\]) referred as part of standard care for contrast-enhancing MRI of the body. The suspicion may be based on a previous imaging procedure such as CT, PET/CT, ultrasound or MRI performed within 12 months prior to ICF signature.
  • The participant is scheduled for a contrast-enhanced MRI examination of the CNS or a body region for clinical reasons and has agreed to have a second contrast-enhanced MRI examination for the purpose of this study.
  • The participant is in a clinically stable condition (i.e., no acute deterioration within 48 hours before enrollment).
  • Female Participants: The participant is a female who is either surgically sterile (has had a documented bilateral oophorectomy, bilateral salpingectomy, and/or documented hysterectomy), postmenopausal (cessation of menses for more than 1 year), or non-lactating, or if of childbearing potential the results of a serum human chorionic gonadotropin pregnancy test, performed at screening and the results of a urine pregnancy test, or serum human chorionic gonadotropin pregnancy test performed prior to each administration of IMP (with the result known before IMP administration), must be negative. Female participants of childbearing potential must agree to use adequate contraception and not harvest or donate eggs from screening until 30 days after final dose of IMP. Such methods include hormonal contraception including oral, intravaginal, transdermal, injectable, and implantable contraceptives; intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion; vasectomized partner. Total abstinence, in accordance with the lifestyle of the participant, is also acceptable.
  • Male Participants: The participant is a male who is surgically sterile (vasectomy or bilateral orchidectomy), a male who is sexually active with a partner who is not of childbearing potential, or a male who is sexually active with a partner of childbearing potential who must agree to use adequate contraception and not harvest or donate sperm from screening until 90 days after final dose of IMP. Adequate contraception for the male participant (and any female partner, if she is of childbearing potential) is defined as using hormonal contraception (including oral, intravaginal, transdermal, injectable or implantable contraceptives), an intrauterine device, or an intrauterine hormone-releasing system, combined with at least one of the following forms of contraception: a diaphragm, a cervical cap, or a condom. Total abstinence, in accordance with the lifestyle of the participant, is also acceptable.

Exclusion Criteria:

  • The participant has previously enrolled in this mangaciclanol study, including participation in an earlier phase or cohort.
  • The participant has a contraindication to MRI examination, such as the presence of a cardiac pacemaker or other electronic devices, presence of ferromagnetic metal foreign bodies in vulnerable positions or within positions that would affect the imaged field of view, presence of certain tattoos that may raise a safety concern for MRI, participant suffering from severe claustrophobia which is not manageable with standard sedation, or participant working as a machinist, welder or metal worker (unless the participant will undergo thorough screening by radiology personnel to rule out the presence of metallic foreign bodies, especially in or near the eyes).
  • Participant with severe cardiovascular disease (e.g., known long QT syndrome including QTc prolongation based on screening ECG, acute myocardial infarction within the past 14 days, unstable angina, congestive heart failure class III/IV by New York Heart Association classification, or acute stroke within the past 48 hours).
  • (Phase 2 only) Participant with an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) within 14 days prior to the first IMP administration.
  • (Phase 3 only) Participant with an eGFR <30 mL/min/1.73m2 calculated using the CKD-EPI within 14 days prior to the first IMP administration.
  • Participant with increased likelihood of hypersensitivity specifically to mangaciclanol, gadolinium or a component of the formulation.
  • Participant has received any non-study contrast agent within 72 hours prior to the first study MRI, or is planning to receive any non-study contrast agent during the trial until 24 ± 4 hours after the second study MRI.
  • Participant has received any investigational product within 30 days or within 5 times the half-life of that drug, whichever is shorter, prior to or concurrent with this study.
  • Participant is expected/scheduled to have any treatment or medical procedure (e.g., chemotherapy, radiotherapy, biopsy, resection, etc.) that may impact aspects of the imaged lesions from the first study MRI up to 24 hours after the second study MRI. (Participants under corticosteroids and/or maintenance chemotherapy with a stable dose at the time of screening visit and throughout the trial can be included).
  • Participant may not be able to complete the study, based on their anticipated life expectancy, or where study participation may compromise the management of the participant, or any other reason that in the judgment of the investigator makes the participant unsuitable for participation in the study.
  • Participant is pregnant or planning to become pregnant, or breast-feeding.
  • Participant is unable or unlikely to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and/or considered unlikely to complete the trial.

Study Design

Enrollment

640 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

active comparator: Phase 2

An initial dose of 0.1 mmol/kg mangaciclanol will be compared to the standard dose of gadobutrol (0.1 mmol/kg) in Cohort 1, in approximately 60 participants.

A second cohort (Cohort 2) may be initiated based on the outcome of the analysis of Cohort 1. This cohort will include approximately 60 participants (higher or lower dose), or 30 participants (same dose), depending on the dose of mangaciclanol selected for further evaluation.

active comparator: Phase 3 mangaciclanol-gadobutrol

Participants with known or highly suspected lesions of CNS or body, randomized to receive treatment sequence mangaciclanol (V2) followed by gadobutrol (V4)

active comparator: Phase 3 gadobutrol-mangaciclanol

Participants with known or highly suspected lesions of CNS or body, randomized to receive treatment sequence gadobutrol (V2) followed by mangaciclanol (V4)

Interventions

Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL

Single intravenous (IV) administration of Mangaciclanol (GEH200486 Injection, 0.5 mmol/mL) followed by a 20mL saline flush

MRI Scan

MRI Scan starting prior to IMP administration and continuing for up to 60 minutes post IMP administration

Gadobutrol

Single intravenous (IV) administration of Gadobutrol (0.1 mmol/kg) followed by a 20mL saline flush

Primary outcome measure

  • Phase 2 Primary Endpoint - Overall diagnostic preference [ Time Frame: 4-47 days ]
  • Phase 3 Primary Endpoint - Lesion visualization criteria [ Time Frame: 4-74 days ]

Central Contacts and Locations

Central contacts

Jay Chahal

+44 7786702088jay.chahal@gehealthcare.com

Locations

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Renovatio Clinical

Recruiting

The Woodlands, Texas, United States, 77380

More Information

Sponsor

GE Healthcare

Last update posted

Jun 29, 2026

Last verified

Apr, 2026

Keywords

  • Contrast-enhanced magnetic resonance imaging (MRI)
  • Mn-based contrast agents (MBCAs)
  • Gd-based contrast agents (GBCAs)
  • Lesion visualization

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by GE Healthcare on 2026-06-29.